Research programme: gene editing therapeutics - Intellia Therapeutics/Novartis

Drug Profile

Research programme: gene editing therapeutics - Intellia Therapeutics/Novartis

Alternative Names: CRISPR/Cas9-based CAR-T cell therapies - Intellia Therapeutics/Novartis; CRISPR/Cas9-based haematopoietic stem cell therapies - Intellia Therapeutics/Novartis

Latest Information Update: 24 Jun 2017

Price : $50

At a glance

  • Originator Intellia Therapeutics
  • Class CAR-T cell therapies; Gene therapies; Stem cell therapies
  • Mechanism of Action Gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 19 Jun 2017 China’s State Intellectual Property Office ("SIPO") announced its intention to grant a patent for CRISPR/Cas9 genome editing technology
  • 02 May 2017 Vilnius University has patent protection for CRISPR-Cas9 genome editing in USa
  • 13 Apr 2017 University of California, University of Vienna, and Charpentier appeals decision by PTAB, which dismissed interference proceedings against Broad Institute, MIT, and Harvard University for a patent related to CRISPR-Cas9 genome editing technology, in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top